Insider Selling: DexCom Inc. (DXCM) CEO Sells 7,000 Shares of Stock
DexCom Inc. (NASDAQ:DXCM) CEO Kevin R. Sayer sold 7,000 shares of the business’s stock in a transaction dated Friday, October 14th. The stock was sold at an average price of $81.87, for a total transaction of $573,090.00. The sale was disclosed in a filing with the SEC, which is available through this hyperlink.
Kevin R. Sayer also recently made the following trade(s):
- On Wednesday, September 14th, Kevin R. Sayer sold 7,000 shares of DexCom stock. The stock was sold at an average price of $91.79, for a total transaction of $642,530.00.
- On Monday, August 15th, Kevin R. Sayer sold 7,000 shares of DexCom stock. The stock was sold at an average price of $90.78, for a total transaction of $635,460.00.
Shares of DexCom Inc. (NASDAQ:DXCM) traded up 0.36% on Monday, hitting $81.97. 374,485 shares of the company’s stock were exchanged. The firm’s market cap is $6.88 billion. The stock’s 50 day moving average is $89.38 and its 200 day moving average is $78.86. DexCom Inc. has a 12 month low of $47.92 and a 12 month high of $96.38.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/10/17/insider-selling-dexcom-inc-dxcm-ceo-sells-7000-shares-of-stock.html
DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.24) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.12) by $0.12. DexCom had a negative net margin of 16.42% and a negative return on equity of 19.68%. The firm had revenue of $137.30 million for the quarter, compared to the consensus estimate of $132.48 million. During the same quarter in the prior year, the company earned ($0.05) earnings per share. The company’s quarterly revenue was up 47.3% compared to the same quarter last year. On average, equities analysts predict that DexCom Inc. will post ($0.57) earnings per share for the current year.
A number of large investors have recently bought and sold shares of the stock. BNP Paribas Arbitrage SA raised its stake in DexCom by 3,320.0% in the third quarter. BNP Paribas Arbitrage SA now owns 1,197 shares of the medical device company’s stock worth $105,000 after buying an additional 1,162 shares in the last quarter. Bellwether Investment Group LLC purchased a new stake in DexCom during the second quarter worth approximately $119,000. Bank of Montreal Can purchased a new stake in DexCom during the second quarter worth approximately $134,000. Capstone Asset Management Co. purchased a new stake in DexCom during the third quarter worth approximately $205,000. Finally, Private Bank & Trust Co. purchased a new stake in DexCom during the third quarter worth approximately $220,000. Institutional investors own 99.28% of the company’s stock.
DXCM has been the topic of several analyst reports. JPMorgan Chase & Co. reissued a “buy” rating on shares of DexCom in a research report on Monday, June 20th. Zacks Investment Research cut shares of DexCom from a “hold” rating to a “sell” rating in a research report on Tuesday, June 28th. Canaccord Genuity reissued a “buy” rating and set a $95.00 price target on shares of DexCom in a research report on Wednesday, July 13th. Jefferies Group restated a “buy” rating and set a $98.00 price objective (up from $90.00) on shares of DexCom in a research note on Friday, July 15th. Finally, Deutsche Bank AG boosted their price objective on shares of DexCom from $90.00 to $98.00 and gave the stock a “buy” rating in a research note on Friday, July 15th. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, twelve have given a buy rating and one has issued a strong buy rating to the stock. DexCom currently has an average rating of “Buy” and an average target price of $95.40.
DexCom Company Profile
Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring systems for ambulatory use by people with diabetes and for use by healthcare providers for the treatment of people with and without diabetes. Its products include SEVEN PLUS, DexCom G4, DexCom G4 PLATINUM, DexCom Share System and DexCom G5 Mobile.
Receive News & Ratings for DexCom Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom Inc. and related companies with MarketBeat.com's FREE daily email newsletter.